Division of Clinical Immunology and Allergy, Department of Internal Medicine, University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):121-30. doi: 10.1007/s00005-010-0067-0. Epub 2010 Feb 14.
T cell epitope-driven vaccine design employs bioinformatic algorithms to identify potential targets of vaccines against infectious diseases or cancer. Potential epitopes can be identified with major histocompatibility complex (MHC)-binding algorithms, and the ability to bind to MHC class I or class II indicates a predominantly CD4(+) or CD8(+) T cell response. Furthermore, an epitope-based vaccine can circumvent evolutionary events favoring immune escape present in native proteins from pathogens. It can also focus on only the most relevant epitopes (i.e. conserved and promiscuous) recognized by the majority of the target population. Mounting evidence points to the critical role of CD4(+) T cells in natural antigen encounter and active immunization. In this paper the need for CD4(+) T cell help in vaccine development, the selection of CD4(+) T cell epitopes for an epitope-based vaccine, and how the approach can be used to induce a protective effect are reviewed.
T 细胞表位驱动的疫苗设计采用生物信息学算法来识别针对传染病或癌症的疫苗的潜在靶标。潜在的表位可以通过主要组织相容性复合体 (MHC)-结合算法来识别,并且与 MHC 类 I 或类 II 的结合能力表明主要是 CD4(+)或 CD8(+) T 细胞反应。此外,基于表位的疫苗可以避免病原体天然蛋白中存在的有利于免疫逃逸的进化事件。它还可以仅针对大多数目标人群识别的最相关表位(即保守和混杂)进行重点关注。越来越多的证据表明 CD4(+) T 细胞在天然抗原接触和主动免疫中起着关键作用。本文综述了在疫苗开发中 CD4(+) T 细胞辅助的必要性、基于表位疫苗中 CD4(+) T 细胞表位的选择,以及如何使用该方法诱导保护作用。